reports
- GlobalData Healthcare Department
Probiodrug AG (PBD) - Financial Analysis Review
Probiodrug AG (PBD) - Financial Analysis Review Summary Probiodrug AG (Probiodrug) is a biopharmaceutical company that conducts research and development of therapies for Alzheimer’s disease. The company provides three pipeline drug candidates such as PQ912, PBD-C06 and PQ1565. Its PQ912 drug candidate is a small molecule glutaminyl cyclase (QC) inhibitor in Phase II clinical trials that inhibits QC-enzyme for animal models. Probiodrug’s PBD-C06 is a monoclonal antibody under evaluation, wh...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.